Pharming (PHAR) Non-Current Deferred Tax Liability (2019 - 2025)

Pharming's Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at -$31.0 million for Q4 2025.

• Quarterly Non-Current Deferred Tax Liability fell 1.55% year-over-year to -$31.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$31.0 million (down 1.55% YoY) and the FY2025 annual result came in at -$31.0 million, down 1.55% from the prior year.
• Non-Current Deferred Tax Liability was -$31.0 million for Q4 2025 at Pharming, down from -$30.5 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at -$21.2 million in Q4 2021 and bottomed at -$31.0 million in Q4 2025.
• A 5-year average of -$27.1 million and a median of -$29.8 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability soared 31.45% — and 2023, when it fell 29.55%.
• Pharming's Non-Current Deferred Tax Liability stood at -$21.2 million in 2021, then declined by 8.28% to -$23.0 million in 2022, then decreased by 29.55% to -$29.8 million in 2023, then fell by 2.63% to -$30.5 million in 2024, then retreated by 1.55% to -$31.0 million in 2025.
• Business Quant data shows PHAR's Non-Current Deferred Tax Liability at -$31.0 million in Q4 2025, -$30.5 million in Q4 2024, and -$29.8 million in Q4 2023.